Search results
Results from the WOW.Com Content Network
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
When taken in combination with dabrafenib the most common side effects include fever, tiredness, nausea, chills, headache, diarrhea, vomiting, joint pain and rash. [5] In May 2013, trametinib was approved as a single-agent by the US Food and Drug Administration for the treatment of people with V600E mutated metastatic melanoma.
Side effects in dogs and cats include hypersalivation, diarrhea, loss of appetite, and vomiting. [12] [16] Eight percent of dogs taking maropitant at doses meant to prevent motion sickness vomited right after, likely due to the local effects maropitant had on the gastrointestinal tract. Small amounts of food beforehand can prevent such post ...
After good results in 2014, the combination was submitted to the European Medical Agency and the US Food and Drug Administration for marketing approval. [ 21 ] In January 2015, trial results compared vemurafenib with the combination of dabrafenib and trametinib for metastatic melanoma.
Its mechanism of action is to target specific blood vessels supplying adipose tissue with blood, cause the vessels to shrink and the fat cells fed by those vessels to undergo apoptosis. [4] TP01 is designed to bind to two receptors, ANXA2 and prohibitin , that are specific to blood vessels supplying white adipose tissue .
Some dog food products differentiate themselves as grain- or carbohydrate-free to offer the consumer an alternative, claiming carbohydrates in pet foods to be fillers with little or no nutritional value. A study published in Nature suggests that domestic dogs' ability to easily metabolize carbohydrates may be a key difference between wolves and ...
Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. [5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered ...
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron.